Clinical treatment of advanced synchronous triple primary malignancies: comprehensive treatment based on targeted therapy

Ying Zhang
Yunjie Ge
Xiaohui Wu
Shuangmei Liu
Department of Internal Medicine,
Municipal Hospital, Qingdao, Shandong,
People’s Republic of China

Abstract: The prevalence of cancer remains high. With the improvement of diagnosis and treatment level and the increase of cancer survivors after treatment, multiple primary tumors are more common than before. The diagnosis and treatment of synchronous multiple primary tumors is more complicated than that of single or metachronous multiple tumors, and patients also suffer more. Because of the different conditions of these patients, lack of large-scale clinical observation data, it is necessary for clinicians to make realistic decisions on the specific conditions of patients. It is a challenge for clinicians to apply the advances of modern medicine to the diagnosis and treatment of such patients so as to prolong their survival time and improve their quality of life. This report describes the survival of an advanced elderly patient with lung, prostate and bladder cancer after receiving targeted therapy-based comprehensive treatment.

Keywords: advanced synchronous triple primary malignancies

Introduction

In recent years, due to the improvement in screening methods, early intervention, diagnostic sensitivities and therapy ways, the prevention, diagnosis and treatment of cancer patients have made great advances, so that the overall survival time and quality of life of cancer patients have made significant progress. This improvement and aging of the population have led to a surge in the number of survivors of secondary multiple tumors, which poses an additional threat in terms of morbidity and mortality. Compared with the general population, cancer survivors had a 14% increased risk of developing a second primary cancer. The incidence of multiple primary cancers ranged from 2.4% to 8%, with a maximum of 17% within 20 years of follow-up. Compared with synchronous primary cancer (59%) and single primary cancer (59%), metachronous cancer (95%), simultaneous concomitant multiple primary tumors had the lowest 5-year survival rate, averaging 1.9 years. Most studies have shown that the prognosis of synchronous primary cancer patients is worse than that of metachronous primary patients. Multiple primary cancers are often understood as simultaneous cancers or metachronous cancers that occur sequentially. Because of the different nature of multiple primary cancers, they should be treated as different tumors, including staging and treatment. These problems make the management of patients with multiple primary tumors continues to be...
a challenge. As some researchers have pointed out, although there are many studies on multiple tumors, the practical implications of managing multiple primary lesions are seldom discussed. In this report, we describe an advanced patient with simultaneous concomitant lung cancer, prostate cancer and bladder cancer who underwent targeted therapy combined with hormonal therapy and surgical treatment and survived for 1 year and 10 months.

This case is extremely rare because the simultaneous occurrence of lung cancer, prostate cancer and bladder cancer with bone metastasis has not been reported in the literature.

Case report
An 81-year-old man never-smoker was referred to our hospital due to cough, sputum and fever continuing for over 2 weeks on Sept 1, 2016. In all the patient’s medical history, he had only suffered from hyperlipidemia and gallbladder stones, and had received surgical treatment for cervical dislocation 5 years ago. He denied previous diseases, including cancer or malignant tumors, and had never received any radiation or chemotherapy, and had never been exposed to any particular substance, such as arsenic. There are only occasional small amounts of alcohol in his life and no history of heavy drinking or alcoholism. Because of the distance of time and the poor medical conditions of many years ago, the patient was unable to account for the cause of death and illness of his parents and family members. Computed tomography (CT) of this patient’s chest showed an abnormal mass shadow in his left lower lung, mediastinal lymph node enlargement. The serum concentration of the serum carcinoembryonic antigen (CEA) was 53.32 ng/mL, and prostate specific antigen (PSA) was >100ng/mL. Abnormal signal loci in the central region of prostate magnetic resonance imaging, the bladder is poorly filled, with several prominent shadow-like sacs on the left side wall. The whole body bone imaging examination showed abnormal bone metabolism, consistent with the signs of multiple bone metastases (Figure 1). The histopathologic findings revealed hypodifferentiated adenocarcinoma after a biopsy specimen obtained by fiber-optic bronchoscopy (Figure 2). After the same detailed understanding of the process of prostate puncture and cystoscopy, the painful experience of bronchoscopy made the patient firmly refuse further invasive examination, because both prostatic puncture and cystoscopy are invasive examination. According to the rules, the clinician must obtain the patient’s consent for invasive examination, otherwise it can not be carried out.

Then, the EGFR mutation status of the specimens obtained by bronchoscopy was investigated, and the result showed both exon 19 deletions and an L858R point in exon 21. Then icotinib (125 mg) (patent number WO2003082830; Zhejiang Bata Pharma Ltd., Hangzhou, People’s Republic of China) was orally administered three times a day after the result was EGFR mutation-positive.

The patient had mild diarrhea after taking icotinib, and obvious relief of cough and chest discomfort, so he did not follow the doctor’s advice to review the chest CT until 3 months later. CT results showed a marked reduction in tumor size (Figure 3).

After 6 months, the patient came back to see the doctor again because the frequency of urination affected his nighttime sleep. The difference is that this time the patient is in good spirits and believes that the doctor can solve his discomfort in urination. The results of urological magnetic resonance imaging (MRI) examination showed irregular enlargement of prostate and abnormal signal (Figure 4), which considered prostate cancer, not excluding left seminal vesicle gland involvement, while the left bladder wall occupied space (Figure 5), pelvic lymph node enlargement. Echocardiographic display of pericardial effusion. The serum concentration of the serum CEA was 3.62 ng/mL, and PSA was >100 ng/mL. The whole body bone imaging examination showed that abnormal bone metabolism was progressive. Urologists again recommend prostate puncture or cystoscopy. Patients refuse invasive examination, hoping to receive minimal suffering treatment according to the expected diagnosis.

Hormonal therapy is recommended in urology. Bicalutamide tablets (Casodex, AstraZeneca GmbH) 50 mg is taken orally once a day and Leuprorelin acetate microspheres sustained release for injection (Beijing Biote Pharmaceutical Co. Ltd) 3.75 mg is given subcutaneously every 4 weeks, strontium dichloride for bone metastasis. Later, the patient’s symptoms improved according to the doctor’s instructions. The patient was not admitted to hospital until September 3, 2017 (4 months after receiving prostate treatment and 11 months after lung cancer targeted treatment) due to frequent urination and increased pain in the lower abdomen. Blood reexamination showed CEA 2.8 ng/mL, PSA 1.18 ng/mL, CT examination showed that the prostate gland is full, with uneven density and calcification, which is consistent with the changes after endocrine
therapy. The left side wall of the bladder is significantly irregularly thickened and involves the lower end of the left ureter, and the left renal pelvis and ureteral dilatation and hydrocele. CT also showed partial nodules decreased in both lungs (considering the metastasis of prostate cancer in the lungs) (Figure 6), new nodules appeared, and pericardial effusion did not change significantly. The whole body bone imaging examination showed abnormal bone metabolism was significantly alleviated after 6 months of hormone therapy for prostate cancer.

Figure 1 The whole body bone imaging examination. (A) Showed abnormal bone metabolism, consistent with the signs of multiple bone metastases: The right side of mandible, chest 11, left side of lumbar 2 vertebra, left side of lumbar 4 vertebra pedicle, sacrum and right side of sacroiliac joint showed increased patchy radioactive uptake, and the right side of pyramidal 8 and 10 showed slightly increased reflective uptake. (B) Showed abnormal bone metabolism was significantly alleviated after 6 months of hormone therapy for prostate cancer.
carcinoma (Figure 7). Nine days after surgery, the patient developed hematuria, bladder irrigation was given and catheterization was retained for 3 weeks. Targeted therapy for lung cancer and treatment for prostate cancer remained unchanged. On April 4, 2018, he was admitted to hospital again because of hematuria and urine urgency. Considering the diagnosis of recurrence of bladder cancer and the patient’s intolerance to surgery, he was given bilateral internal iliac artery angiography plus superselective embolization, and gemcitabine 1,000 mg was applied during the operation. On May 16, 2018, the patient was admitted to the hospital again due to urination urgency, urination pain and fever for 2 days. After anti-infection and improvement of the general condition, the patient’s symptoms improved. After that, the original treatment was maintained. On May 22, serum creatinine rose to 182.97 µmol/L, and the patient refused further treatment. Due to dizziness and head swelling for 10 days, aggravated nausea and vomiting for 1 day, he was re-admitted to the hospital on June 27, 2018. Since then, the patient had stopped taking all oral medications, including icotinib. The blood test results showed that blood creatinine 887.14 µmol/L, BUN 51.08 mmol/L, blood potassium 5.9 mmol/L, hemoglobin 58 g/L, CEA 16.7 ng/mL, PSA 0.063 ng/mL, and arterial blood gas analysis showed pH 7.34. The results of ultrasonography showed hydronephrosis with bilateral ureteral dilatation, irregular thickening of bladder wall with solid nodules and intraluminal sediment. Diagnosis: renal failure, hydronephrosis, metabolic acidosis, electrolyte disturbance. The patient and his family members refused the treatment of hemofiltration, hemodialysis and nephrostomy. The patient died suddenly at home on July 25, 2018, and his family refused to perform the autopsy. Written

Figure 2 Hematoxylin–eosin-stained (10*20) biopsy specimens obtained by bronchoscopy. The tumor cells are large with highly atypical nuclei, and the histology and immunohistochemical findings suggest adenocarcinoma. Immunohistochemical results: TTF-1(+), CK7(+), P63(-), P40(-), NapsinA(+).

Figure 3 The tumor was compared between lung window and mediastinal window on chest CT. Chest CT showed that the lung tumor size was significantly reduced in January 19, 2017 (B, D) compared with September 1, 2016 (A, C).
Figure 4 Prostate MRI examination. Abnormal signal foci in the central region of prostate magnetic resonance imaging in September 1, 2016 (A), irregular enlargement of prostate and abnormal signal in April 17, 2017 (B), which was considered as prostate cancer.

Figure 5 Bladder MRI examination. In September 1, 2016 (A) the bladder was poorly filled, with several prominent shadow-like sacs on the left side wall; sacs on the left side wall had grown up to be occupied space in April 17, 2017 (B).

Figure 6 Chest CT. Partial nodules decreased in both lungs (considering the metastasis of prostate cancer in the lungs) in September 3, 2017 (B, D) compared with April 12, 2016 (A, C).
informed consent has been provided by the patient’s next-of-kin to have the case details and any accompanying images published.

**Discussion**

For patients without early screening, most of the time when malignant tumors are found was when patients go to hospital because of obvious symptoms, while most of the symptoms appear in the late stage of malignant tumors. Evidence suggests that genetic disorders and somatic mutations, behavioral influences, lifestyles and comorbidities usually affect the prognosis of patients. Studies suggest that age, ethnic background, smoking, alcohol abuse, overweight, gender, family history and previous treatment are risk factors for multiple primary tumors, and the risk of further primary cancer may increase due to the persistent effects of genetic and behavioral risk factors, and increased diagnostic sensitivity. According to previous studies, patients with bladder cancer have an increased risk of lung cancer and prostate cancer, and patients who initially develop bladder, prostate cancer are more likely to develop a second malignancy. In Levi et al’s study on second primary cancer, the most common sites of the first tumor include prostate, bladder/ureter squamous cell carcinoma, etc., and the most common sites of the second tumor include lung and prostate. Different variations of CDKN2B-AS1 loci are known to be associated with lung adenocarcinoma and prostate cancer. The 10 most common subsequent primary cancers after lung and bronchus cancer include prostate cancer and urinary bladder cancer. As high as 5.0% of the patients with lung cancer were patients with multiple malignant tumors. As the second malignant tumor, lung cancer develops more frequently in patients with multiple malignant tumors. Synchronous cancers are more pronounced in old age than metachronous cancers.

Table 1 summarizes the cases with synchronous triple primary malignancies including lung cancer. As can be easily seen, triple synchronous primary lung cancer is the most frequently reported.

In patients with synchronous multiple primaries, it should be noted that in most cases, the treatment recommended by the doctor is personal decision, not general treatment recommendation, and these treatments are not based on prospective experimental evidence, but on “realistic” examples of challenging clinical situations.

The literature on the phenomenon of synchronous triple primary malignancies: lung cancer, prostate cancer and bladder cancer in a single patient are reviewed which included a PubMed database search from 1980 to December 2017 of reported cases in English. The search was performed by using various combinations of searching keywords involving “(synchronous triple primary malignancies OR three simultaneous cancers OR multiple concurrent cancers OR multiple primary carcinomas) AND (lung carcinoma OR lung cancer OR bronchiogenic cancer OR bronchiogenic carcinoma OR lung adenocarcinoma) AND (prostatic carcinoma OR prostatic cancer OR prostate carcinoma) AND (carcinoma of urinary bladder OR bladder cancer OR bladder carcinoma)”. There were only two case reports referring to patients with these three primary malignancies. In the case reported by Koutsovoulos et al in 2005, the first tumor was a urinary bladder transitional cell carcinoma, which was followed by metachronous prostate adenocarcinoma and then by small cell lung carcinoma which was revealed 7 months later. Bladder cancer and prostate cancer had undergone surgery, while small cell lung cancer had undergone chemotherapy, and the patient died of the toxicity of the first chemotherapy. The other case reported by Otrock et al also in 2005 showed that the patient was first diagnosed with lung adenosquamous carcinoma and underwent pneumonectomy, adjuvant chemotherapy and radiotherapy. Eleven years later, he was diagnosed with bladder cancer and prostate cancer and underwent surgery. One and a half years after that he was diagnosed with breast cancer and received chemotherapy. One year later, he died of septic shock. Our case is the first one of clinical diagnosis and...
Table 1 The previously reported examples of synchronous triple primary malignancies including lung cancer

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Age (years)/gender</th>
<th>Malignancies</th>
<th>Treatment</th>
<th>Survival time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patel et al</td>
<td>1985</td>
<td>71/F</td>
<td>GA + LSq + BDC</td>
<td>PL + M + HG</td>
<td>Well 2 years</td>
</tr>
<tr>
<td>Jung-Legg et al</td>
<td>1986</td>
<td>49/M</td>
<td>BC + SCLC + LA</td>
<td>PL + chemotherapy</td>
<td>Dead after 3 years</td>
</tr>
<tr>
<td>Badiali et al</td>
<td>1987</td>
<td>63/M</td>
<td>LA + SCLC + LSq</td>
<td>PL + P</td>
<td>Intraoperative death</td>
</tr>
<tr>
<td>Taira et al</td>
<td>1996</td>
<td>74/M</td>
<td>DC + PC + LC</td>
<td>PD + PLR</td>
<td>No description</td>
</tr>
<tr>
<td>Hamada et al</td>
<td>2000</td>
<td>62/M</td>
<td>LC + gastric cancer + thyroid cancer</td>
<td>PL + EMR</td>
<td>No description</td>
</tr>
<tr>
<td>Tamura et al</td>
<td>2001</td>
<td>65/M</td>
<td>LC + UBC + esophagus cancer</td>
<td>Chemotherapy + radiochemotherapy</td>
<td>Died of Disease</td>
</tr>
<tr>
<td>Brun et al</td>
<td>2002</td>
<td>57/M</td>
<td>LA + SCLC + LSq</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Tokuchi et al</td>
<td>2003</td>
<td>66/M</td>
<td>NHL + LLC + LSq</td>
<td>Chemotherapy + chemotherapy</td>
<td>Died of Disease</td>
</tr>
<tr>
<td>Froio et al</td>
<td>2008</td>
<td>59/M</td>
<td>LA + SCLC + LSq</td>
<td>Surgery</td>
<td>Well 27 months</td>
</tr>
<tr>
<td>Jeon et al</td>
<td>2008</td>
<td>74/M</td>
<td>Esophageal + laryngeal cancer + LC</td>
<td>—</td>
<td>Well &gt;2 years</td>
</tr>
<tr>
<td>Ishiura et al</td>
<td>2008</td>
<td>77/M</td>
<td>LC + DAS + UCB</td>
<td>Chemotherapy</td>
<td>—</td>
</tr>
<tr>
<td>Iqbal et al</td>
<td>2008</td>
<td>71/M</td>
<td>LSq + LaSq + TSPC</td>
<td>Radiotherapy + surgery</td>
<td>Died of Disease</td>
</tr>
<tr>
<td>Ma et al</td>
<td>2010</td>
<td>75/M</td>
<td>LA + LA + LBAC</td>
<td>Surgically resected by minimal invasive approach</td>
<td>—</td>
</tr>
<tr>
<td>Okita et al</td>
<td>2010</td>
<td>71/F</td>
<td>Well-differentiated LSq + well-differentiated LSq + poorly-differentiated LSq</td>
<td>PL</td>
<td>Well 39 months</td>
</tr>
<tr>
<td>Ito et al</td>
<td>2012</td>
<td>78/F</td>
<td>LSq + LA + LA</td>
<td>PL</td>
<td>—</td>
</tr>
<tr>
<td>Zardo et al</td>
<td>2014</td>
<td>72/F</td>
<td>LA + SCLC + BSq</td>
<td>PL twice</td>
<td>—</td>
</tr>
<tr>
<td>Yoon et al</td>
<td>2014</td>
<td>72/M</td>
<td>LMA + LA + LSq</td>
<td>PL + chemotherapy</td>
<td>—</td>
</tr>
<tr>
<td>Jin et al</td>
<td>2015</td>
<td>66/F</td>
<td>BDC + LA + LA</td>
<td>PM + hormonal therapy + radiotherapy</td>
<td>—</td>
</tr>
<tr>
<td>Song et al</td>
<td>2016</td>
<td>63/F</td>
<td>ESq + LA + thymoma</td>
<td>PL + lymphadenectomy + radical thymectomy</td>
<td>—</td>
</tr>
<tr>
<td>Kim et al</td>
<td>2017</td>
<td>65/M</td>
<td>Laryngeal cancer + SCLC + LSq</td>
<td>Chemoradiotherapy + chemotherapy</td>
<td>—</td>
</tr>
<tr>
<td>Doi et al</td>
<td>2017</td>
<td>74/M</td>
<td>Synchronous triple primary LA</td>
<td>Surgery</td>
<td>—</td>
</tr>
<tr>
<td>Kashif et al</td>
<td>2017</td>
<td>63/M</td>
<td>LA + BSq + mixed small and large cell neuroendocrine carcinoma.</td>
<td>Chemotherapy</td>
<td>—</td>
</tr>
<tr>
<td>Takada et al</td>
<td>2017</td>
<td>71/F</td>
<td>Breast cancer + LA + duodenal papillary carcinoma.</td>
<td>Refuse treatment</td>
<td>—</td>
</tr>
</tbody>
</table>

Abbreviations: LC, lung carcinoma; GA, gastric adenocarcinoma; LSq, lung squamous cell carcinoma; BDC, breast ductal carcinoma; BC, bronchial carcinoid; SCLC, small cell lung cancer; LA, lung adenocarcinoma; DC, duodenal carcinoma; PC, pancreatic carcinoma; UBC, urinary bladder carcinoma; NHL, Non-Hodgkin's lymphoma; LLC, lung large cell carcinoma; DAS, differentiated adenocarcinoma of the stomach; UCB, urothelial carcinoma of the bladder; LaSq, laryngeal squamous cell carcinoma; TSPC, thyroid sclerosing papillary carcinoma; AB, adenocarcinoma of the bronchus; LBAC, lung bronchioalveolar carcinoma; BSq, squamous cell carcinoma of the bronchus; LMA, lung mucinous adenocarcinoma; BDC, ductal carcinoma of breast; ESq, esophageal squamous cell carcinomas; PL, pulmonary lobectomy; M, mastectomy; HG, hemigastrectomy; P, pneumonectomy; PD, pancreatoduodenectomy; PLR, partial lung resection; EMR, endoscopic mucosal resection; PM, partial mastectomy; —, no description or not in English.
treatment on how doctors should deal with the three primary malignancies involving separate organs of lung cancer, prostate cancer and bladder cancer occurring in the same patient at the same time.

For this patient, the three tumors were clearly demonstrated by imaging examination at the time of initial diagnosis and were present at the same time. The presence of bone metastases suggests that the disease is at an advanced stage. The diagnosis of lung cancer and bladder cancer was made after obtaining pathological samples. The diagnosis of prostate cancer was based on the patient’s symptoms, imaging characteristics and PSA test results. After hormonal treatment, the patient’s symptoms improved, the PSA value decreased and some of the lung nodes considered as metastases of prostate cancer decreased significantly, thus further clarifying the diagnosis of prostate cancer.

Subsequently, targeted therapy for lung cancer eliminates patients’ fear of cancer therapy and strengthens patients’ confidence in treatment, because in patients’ mind, cancer treatment, whether chemotherapy or radiotherapy, will have painful digestive tract symptoms or fatigue, hair loss, etc., not only is targeted therapy less painful, simpler to administer, but it is also very effective, and its benefits exceed expectations too much. All of these made it easier for doctors to make decisions about the next treatment for patients. The effect of prostate cancer treatment is in line with doctors’ expectations as well as patients’ requirements and wishes: good results, less suffering. The treatment of bladder cancer causes tremendous suffering: surgery, postoperative bleeding, infection, relapse, severe physical wastage until cachexia. Cachexia is also a common manifestation of advanced cancer in many patients. There is nothing we could do to see the patient’s difficulties at that time. However, the family members of the patients were satisfied with the treatment they received throughout the course of the disease.

Diagnostic stage is another important prognostic factor. As the disease progresses, the decline in survival indicates the importance of screening and early detection. For synchronous multiple primary tumors, whether from diagnosis to treatment, it is more complex than single or metachronous multiple tumors, which brings more suffering to patients. Although all three types of tumors were present at the time of admission, it cannot be ruled out that the three types of tumors did not initially grow at the same time, especially the bladder cancer that was finally treated. If it could be detected and treated at an early stage, the prognosis of the patient will be different.

In all aspects of clinical work, doctors first treat the most painful and life-threatening parts of patients, and the principle is the same in the case of multiple cancers. No matter what the diagnostic results are, clinicians should treat patients with a scientific attitude of respecting patients’ wishes and on the premise of minimizing patients’ pain, not just as scientific research. From this point of view, targeted therapy really reflects the progress of modern science and brings good news to patients, especially cancer patients. The slight side effects of drugs also make it more feasible for doctors to make a definite diagnosis by observing the reaction of the disease to drugs after direct medication, which can avoid the pain of invasive examinations and be more acceptable to patients.

Disclosure
The authors report no conflicts of interest in this work.

References
27. Badiali P, Alloisio M, Lombardi L. Synchronous triple carcinoma of
24. Doi T, Sakamoto T. Synchronous triple primary lung adenocarcino-
22. Koutsopoulos AV, Dambaki KI, Datseris G, Giannikaki E.
21. Romaszko A,
18. Levi F, Randimbison L, Rafael BM, Manuela MC, La Vecchia C.
17. Coyte A, Morrison DS, Philip M. Second primary cancer risk - the
6. dox:0000000085
3. 2014;85(1):96
2. 2010;90(3):e38
0. Epub 2013 Oct 17. doi:10.1177/0218253X063002005
7. 2017;7(1):6451. doi:10.1038/s41598-017-06763-2
6. 2015;120(10):5302.
4. 2012;5302.
1. 2009;9(9):946–949. doi:10.1097/01.smj.0000173086.37625.e2
0. 2002;23:4329.
8. 1986;85(1):96
6. 2000000085
5. 2000000085
2. 1985;120(10):5302.